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to provide an optimal quality of life, especially duringIntroduction
the early phase of endocrine treatment and, if possible,
with preservation of sexual function?The endocrine treatment of prostate cancer has changed
rapidly in the last few years, a change made possible The present author summarized the issue of the endo-
crine treatment of prostate cancer in the recent editionand necessary because of several important develop-
ments. Maximal androgen blockade (MAB), which has of Campbell’s Urology [1]. That chapter was written in
1996 and many aspects are now outdated; the presentoccupied clinical research and resources for more than
10 years, has found a modest but clearly defined place review attempts to provide an update, to present a view
on future research necessities and to anticipate clinicalin the armamentarium of the endocrine management of
metastatic prostate cancer. This development arrests developments.
research potential, eliminates the need to use MAB as
the ‘gold standard’ in metastatic and nonmetastatic Maximal androgen blockade
disease and allows concentration on other relevant issues
which have not been resolved, but which are of great MAB as a concept of treatment for prostate cancer is the
simultaneous complete elimination or blockade of testicu-importance for the further development of the field. Such
unresolved issues are the question of early vs delayed lar and adrenal androgens. In the literature, the syn-
onyms complete androgen withdrawal, completetreatment, the value of adjuvant endocrine treatment,
the evaluation of intermittent treatment, the possibility androgen blockade and total androgen blockade are
used. The concept was first suggested by investigatorsof using very early endocrine treatment, aspects related
to endocrine prevention, and the possibility of preserving from Italy and Germany in the 1960s and 1970s. The
first randomized controlled study which tested MAB wasquality of life, especially as it is related to sexual perform-
ance for at least some period. the EORTC Genitourinary (GU) Group protocol 30805.
This protocol was developed in 1979 and comparedAnother important aspect is not related to treatment,
but to the disease. Endocrine treatment is bound to MAB achieved by castration plus cyproterone acetate
(CPA) 150 mg/day to castration as a standard treatment,change because prostate cancer is diagnosed much ear-
lier in life and with more favourable disease character- and to DES 1 mg in the third arm; 335 patients with
metastatic disease were recruited. The final analysis [2]istics. Prostate cancer is more frequently treated by
potentially curative means, but up to 30–40% of such showed no diCerences in time to progression and overall
survival among the three treatment arms. In 1983,patients may escape such treatment and will eventually
require early or delayed endocrine treatment. The dur- based on experimental findings, Labrie et al. [3] began
to popularize the concept on the basis of a very smallation of endocrine treatment in patients who present
with signs of biochemical progression after radiotherapy phase II study. Subsequently, many randomized com-
parative studies using various forms of MAB have beenor radical prostatectomy likely to be very much longer
than ever experienced before. How can we cope with carried out in the hope that MAB would significantly
delay the progression to endocrine independence ofthis situation without imposing unacceptable side-eCects,
which are related to such long durations of endocrine prostate cancer, and eventually prolong survival. Among
more than 20 studies that address the issue, there weretreatment? Which aspects of endocrine treatment need
to be studied to provide future forms of endocrine two major protocols that seemed to fulfil these hopes,
and to establish MAB as the standard treatment formanagement that are adapted to individual clinical
situations, the need to prevent long-term side-eCects, e.g. metastatic prostate cancer [4,5]. However, methodologi-
cal problems around the largest of these studies, protocolosteoporosis, anaemia, and muscle wasting, the necessity
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0036 of the South West Oncology Group (SWOG)/ included the individual data of 5710 patients, of whom
3283 had died. Another description of the meta-analysis,Intergroup [4] cast doubt on the validity of these data
early on, mainly because the LHRH agonist in the control which is in many respects complementary, was given by
Dalesio et al. [8]. Unfortunately, the data from threearm was used without antiandrogen protection in the
initial phase of treatment, and diCerences in time to suitable trials could not be obtained. The endpoint of the
analysis was the 5-year overall survival; separate analy-progression suggested an eCect of ‘flare’ in the control
arm. The SWOG/Intergroup decided subsequently to ses for each treatment regimen were also carried out,
and a common analysis of all trials together. Of allcarry out another study and to replace the LHRH arm
by castration, as had been done in the similar protocol patients, 13% had nonmetastatic disease; a separate
analysis of those with metastatic disease with and with-of the EORTC GU Group [5]. The results of this latter
protocol (SWOG/Intergroup Study 105) together with out M0 cases did not alter the final results. While there
were diCerences in 5-year survival, mainly related to thethe results of a comprehensive meta-analysis have been
decisive in judging the true value of MAB. The data use of three diCerent antiandrogens (flutamide, nilutam-
ide and CPA), in none of these subgroup analyses wasresulting from these two studies will now be reviewed.
there a significant improvement in 5-year survival;
Fig. 1. shows the survival estimates for all 5710 patients.
The meta-analysis
There was an advantage for MAB at 5 years of 3.5%,
which was not statistically significant. This meta-Why choose a meta-analysis, when a randomized study
should be the most valid way of testing treatment analysis is currently being updated; the total number
of patients is now #7500, with #5200 deaths.principles? Apparently this is not so; if only small or no
diCerences exist between treatment regimens, a very
large sample is necessary. Clinical trials, even if ran-
domized, usually do not have the necessary power. In
this situation, there is a some chance that even valid
trials with the same methodology can lead to variable
results. The chance of finding a positive or negative
result in a situation where in fact no diCerence exists is
estimated to be #10%. This error can be avoided by a
meta-analysis. Another reason to use meta-analyses is
the possibility of avoiding publication bias and the bias
resulting from not considering papers written in lan-
guages that are diBcult to access. This has been called
the ‘Tower of Babel’ bias. Publication bias results from
the reluctance of study groups, authors and publishers
to present and accept negative results for publication. A
meta-analysis or overview analysis must include all
studies, including those that are unpublished. A meta-
analysis must access the original data, as the use of
published data alone is unacceptable. Because a meta-
analysis often has to disregard details which are
addressed in individual trials, such as important prognos-
tic factors, the meta-analysis has been blamed for ‘com-
paring apples and pears’. However, these pitfalls can be
avoided by running multiple analyses in which patients
are separated according to such factors. Another prere-
quisite for conducting a meta-analysis is that all trials
conducted before a fixed date are included. The relative
value of large randomized trials and meta-analysis has
recently been discussed in depth by LeLorier et al. [6].
Almost all trials using MAB have been included in a
meta-analysis conducted by the Prostate Cancer Trialists
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Cooperative Group (PCTCG) [7]. This study included 22 Fig. 1. Survival in 22 randomized prostate cancer trials of
of 25 randomized studies of various regimens of MAB, MAB+castration (green) vs castration alone (red); 5710 patients,
3283 deaths (from [7], with permission).which were initiated before December 1989. The analysis
© 1999 BJU International 83, 161–170
ENDOCRINE TREATMENT OF PROSTATE CANCER 163
Considering the negative outcome of the studies that progression to hormone-independence and death from
prostate cancer. If a decrease of PSA to <4.0 ng/mLhave been added, it cannot be expected that there will
be a larger diCerence in favour of MAB. However, was considered as a response, there was a significant
advantage in the proportion of responses in favour ofconsidering the increase in power, a diCerence of #3%
may be statistically significant. The question will then the flutamide group (OF 80%, OP 68%, P=0.001).
Clearly, this is not reflected in an advantage for the mainbe; should every patient with metastatic prostate cancer
receive MAB, to produce a 3.5% advantage in 5-year endpoints of the trial. In this trial, PSA cannot be
considered a surrogate endpoint.survival? Side-eCects, other therapeutic options, quality
of life and cost will have to be considered in this context. Reviewing the results of this largest single, well-
controlled study together with the results of the meta-
analysis, MAB is clearly not the treatment of choice for
SWOG/Intergroup study 105
metastatic prostate cancer. It is possible that subgroups
of patients would benefit from MAB, but these have notRecently, the results of this important protocol have
been published [9]; the study compares bilateral orchi- been properly identified.
dectomy combined with flutamide vs placebo in patients
with metastatic prostate cancer. The study is double-
Remaining indications for MAB
blind for flutamide and placebo; 1387 patients were
randomized between 15 December 1989 and If endocrine treatment by the use of an LHRH agonist is
chosen, an antiandrogen should be added before the15 September 1994. At the time of the analysis presented
in 1997, the study was mature. The main endpoints are initiation of, or at the time of treatment to suppress
disease ‘flare’. Many trials that have compared MAB tosurvival and progression-free survival. A stratification
by minimal disease (MD, 283 patients) and extensive more standard forms of endocrine treatment, and which
have studied response as a study endpoint, have founddisease (ED, 1088 patients) was carried out to confirm
diCerences found in the earlier protocol [4], in which that tumour markers become normal and symptoms of
prostate cancer resolve more quickly, and often signifi-MAB seemed to be more eCective in patients with MD.
The follow-up was 3 monthly and the results of protocol cantly more frequently (as in SWOG/Int 105), than with
castration or the use of LHRH agonists. The use of MAB,105, as they were presented in 1997, are reproduced in
Table 1. Of 1387 patients, 1371 were eligible; more at least temporarily, should be considered in patients
who initially present with symptoms related to prostatethan half of all patients have progressed and/or died.
Toxicity favoured the placebo group, with significant cancer (e.g. bone pain, neurological symptoms, impaired
micturition). A faster and more pronounced responsediCerences for diarrhoea (P<0.001) and anaemia (P=
0.046) and a trend toward more favourable liver func- can be expected; however, this may not be expected to
translate into an advantage in time to progressiontion. The results are given for the treatment groups of
orchidectomy plus flutamide (OF) and orchidectomy plus and/or survival.
The role of second-line endocrine treatment withplacebo (OP); similar numbers of patients were eligible
for evaluation. Also, the proportions of patients with MD antiandrogens needs to be further investigated; available
information is old and poorly controlled. Furtherand ED were similar in the two treatment groups. There
were no significant diCerences in median or overall research to identify subgroups that may benefit from
MAB may be warranted. However, without repeatingsurvival.
An important question in the further exploration of very large studies, this may prove to be impossible.
endocrine treatment is whether PSA could be used as a
surrogate marker. This would allow a shortcut in the
trial design by avoiding the necessity of waiting for
Table 1 The SWOG/INT 105 trial, a
randomized study of metastatic prostate
cancer comparing castration and placebo
versus castration and flutamide in a
double-blind protocol (after [9])
Median times (months)
Group* Eligible MD* ED* PF* Survival
all/MD all/MD
OF 690 139 551 20/50 32/54
OP 681 144 537 19/47 30/51
*OF, orchidectomy+flutamide; OP, orchidectomy+placebo; MD, minimal disease; ED,
extensive disease; PF, progression-free.
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death are used for each stage of the disease, taken fromEarly vs delayed endocrine treatment
the available literature on the natural history and from
clinical trials of prostate cancer. In Fig. 2-I, the clinical
The scope of the problem
course of M1 disease is depicted; the median survival
rates for M+ disease are extrapolated from two EORTCThe issue of early vs delayed treatment used to be
debated mainly for two clinical situations; (i) should protocols [2,11], which used MAB and standard treatment
without showing a diCerence; the data given in [7] andlocally advanced but nonmetastatic disease be treated
immediately, or once metastatic progression had [9] are similar. Half of the patients with metastatic
prostate cancer are dead within 30–36 months. To thisoccurred?; and (ii) should patients with lymph node
metastases be treated immediately after diagnosis, or period of 3 years from the diagnosis of metastatic disease
to death, one year was added to account for the earlierwhenever metastatic progression occurs?
Recently, the scope of the problem has become much diagnosis of M+ disease during follow-up. A 4-year period
from the diagnosis of M1 to death was included in allwider. Evidence for tumour progression is no longer based
on an elevation of acid phosphatase, alkaline phosphatase, time estimates in Fig. 2-II–IV. Fig. 2-II, which relates to
N+M0 disease, shows a drastically longer time frompositive bone scans, metastases visible on X-rays and
complaints of patients related to various types of pro- diagnosis to metastatic progression. In a sample of 34
cases from a randomized prospective study of N+M0gression, including local progression. Local progression
after potentially curative management and metastatic cases (EORTC protocol 30846) the median time to pro-
gression in 34 treated patients was 6 years [12]; T3progression of any type are heralded long before metast-
ases can be diagnosed by a rise in the serum level of PSA. prostate cancer seems to be quite similar to N+M0
disease, but only a few observations on the natural historyThe availability of PSA as a marker of ‘biochemical
progression’ has advanced by some years the possibility are available. From the placebo groups to which delayed
treatment was applied within the Veterans Administrativeof identifying tumour progression and, if this is considered
an indication for treatment, also increased the time during Cooperative Urological Group (VACURG) studies 1 and 2
[13], median times of almost 7 years (study 1) and 4 yearswhich endocrine treatment might be applied. Figure 2
shows an attempt to quantify this changing situation. (study 2) can be extrapolated for progression from stage
3 to stage 4. The mean time to progression to metastaticEstimates of median times to clinical progression and
disease of nonmetastatic patients in the MRC study (MRC
Prostate Cancer Working Party, [10]) was 27 months.
Adolfsson et al. [14] found a median time to progression
in T3 G1+2 disease of about 7 years. A 4-year period is
inserted for progression to M+ disease in Fig. 2-III, relat-
ing to T3 disease. These diCerences show how relative
and inaccurate such historical comparisons may be. The
assumption made for N+and T3 disease, that the time
from metastatic progression to death is comparable to
cases presenting with metastases at diagnosis, may also
be very inaccurate. Within a follow-up scheme, metastatic
disease may be detected much earlier and therefore this
period may be longer. Obviously, the time of overall
survival is also influenced by age at diagnosis. However,
to make the point of this discussion, exact estimates are
unnecessary. Figure 2-IV is based on solid information
and relates to men who presented with apparently locally
confined disease (T2), who underwent radical prostatec-
tomy, and subsequently suCered progression. Median
times from radical prostatectomy to PSA progression, and
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Fig. 2. The estimated median times to biochemical and clinical from there to metastatic progression and death, were
progression, and to death for each stage of prostate cancer at recently reported based on the data from the Johns
diagnosis. (PD, progressive disease; D, death). *, Median times with Hopkins Institute. The median time from PSA progression
delayed treatment and early treatment are around 20 and 60
to metastatic progression in this series was #8 years, butmonths. I, M+[2,11]. II, N+MO[12]PD on delayed treatment,
depended on prognostic factors such as grade [15]; in thetime of I added. III, T3MO[13,10]. IV, T2 progression after radical
Rotterdam radical prostatectomy series, the respectiveprostatectomy [15,16]. V, T2(T1c)[17,18] (after watchful waiting)
disease specific. VI, T1a[19,20,21]. value was 6 years [16]. These data show that locally
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confined disease, even if it progresses after radical prosta- course, or even to prostate cancer just diagnosed in
locally confined stages? There are currently no answerstectomy, on average has a slow course and may be
associated with a median duration of untreated and to these questions. However, the clinician who wishes
to apply early treatment in very early stages of thetreated natural history of about 12–13 years. Similar
projections can be made using the data of Johansson et al. disease needs to be aware of the natural course for each
stage, as it is roughly indicated in Fig. 2. Are we doing[17] and Adolfsson et al. [18], but have the disadvantage
of excluding grade 3 disease. Figure 2-VI depicts the more harm than good if we treat patients for periods of
10 years by endocrine means? It will be shown belownatural course of truly focal disease (T1a), as it is identified
as an incidental finding in benign prostatic specimens that the expected side-eCects will have to be matched by
a significant prolongation of life for this to be acceptable.removed for symptomatic BPH. Only one report gives a
median time to progression, of #13.5 years for A1 disease Meanwhile, the available information arising from ran-
domized studies of early vs delayed endocrine treatmentin 143 patients [19]. This median time can be extrapolated
from Kaplan-Meier projections. Epstein et al. [20] reported remain to be reviewed.
16% progression with 96 months of follow-up, and Blute
et al. [21] 26.6% with 10.2 years of follow-up. It is
The VACURG studies
estimated that the median time to clinical progression
may be 13–15 years. The lead-time, i.e. the time by The first study that addressed this question, albeit
indirectly, was VACURG study 1, a randomized study ofwhich the diagnosis is advanced by the use of early
detection regimens, e.g. achievable using PSA-driven patients with locally extensive and metastatic prostate
cancer, comparing 5 mg DES with castration, toscreening, may be 4–10 years [22,23]. In future, with
increasing screening for prostate cancer, this amount of castration+5 mg DES, and to placebo [13,26]. In this
study, when progression to symptomatic metastatic dis-time may have to be added to the clinical course of many
patients. This also means that there will be a shift from ease occurred, 44% of the patients randomized to placebo
transferred to active endocrine treatment. Because theremore extensive to less extensive disease at the time of
diagnosis. This trend is confirmed by many recent studies was no diCerence in overall survival, comparing the
placebo group with the active treatment groups, one ofin the USA, and on the European continent [24,25].
How does all this relate to the question of early vs the conclusions of the study was that it did not matter
whether treatment was instituted early or later duringdelayed endocrine treatment? Obviously, if for example
in Fig. 2-IV, the situation of PSA progression after radical the clinical course. VACURG study 2, which included
low dosages of DES (0.2 and 1.0 mg), was set up toprostatectomy (or radiotherapy), endocrine treatment is
given at the time of PSA elevation, the duration of exclude the cardiovascular toxicity seen in study 1 with
5 mg DES. Study 2 was discontinued because again, inendocrine treatment will be drastically increased. This
duration is unknown at present. However, the median the 5 mg DES arm of the study, there was an excess of
cardiovascular death. With only 506 patients ran-time to metastatic progression without endocrine treat-
ment is 6–8 years. Endocrine treatment periods of domized (475 were randomized to each of the four
treatment groups in study 1), the power of this study10 years in this and similar situations must be antici-
pated. Also, the application of this treatment will increase was limited. However, the patients treated with 1 mg
DES showed a significant advantage in overall survivalas more patients will be diagnosed with locally confined
disease in the future, and will receive potentially curative over the placebo group and the other DES groups. This
study was extensively analysed and as a result the advicetreatment. Obviously, the side-eCects of endocrine treat-
ment over very long periods will diCer importantly from about early vs delayed endocrine treatment resulting
from study 1 was revised. The final conclusion was thatthose that are experienced in patients who present with
locally advanced or metastatic disease, because of the younger patients with poorly diCerentiated tumours
should be treated immediately, and that older patientsmuch longer duration of treatment. This issue will be
dealt with later in this article. and patients with low-grade disease (Gleason score 2–6)
probably do not need early hormone therapy [13].In this context, what is early endocrine treatment? Is
it treatment given at the time of diagnosis of metastatic
disease, of lymph node positive disease, at the time of
The MRC trial
PSA progression, or at the time of diagnosis of any type
of prostate cancer? If we examine the issue of early vs The conclusions from VACURG Study 2 have not found
widespread acceptance. However, patients and treatingdelayed endocrine treatment in metastatic disease, locally
extensive disease, or in lymph node positive disease, are urologists are reluctant to see tumours progress with
rising PSA levels and without treatment. It is probablythe results obtained applicable to situations where signs
of progression are detected much earlier in the clinical mainly for this reason that early endocrine treatment is
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used increasingly often. The only truly randomized study unavailable. Also, it is very unclear whether the prelimi-
nary information that is available can be applied to theaddressing the issue has recently been published by the
MRC Prostate Cancer Working Party Investigators Group situation of very early progression, such as a minimal
rise in PSA level after radical prostatectomy or radio-[10] (subsequently referred to as the MRC study). The
study was designed to compare the eCect of early endo- therapy, or whether the question of early vs delayed
treatment will find diCerent answers by disease stage.crine treatment vs delayed endocrine treatment in
patients with locally extensive or asymptomatic meta- The treating urologist and the patient have to be aware
of the long duration of endocrine treatment, if it isstatic prostate cancer, which was previously untreated.
A total of 934 patients were randomized, 469 to immedi- applied early, and of the accumulation of side-eCects
that may occur with prolonged treatment.ate and 465 to deferred treatment (503 M0, 261 M1
and 174 Mx). Of the patients who died, 67% did so from What are the potential benefits and pitfalls of early vs
delayed endocrine treatment? Take the example of aprostate cancer. There was a significant diCerence in
favour of immediate treatment for overall survival of all patient with an intact libido and who is sexually active
in some way, not necessarily with intact erections; he ispatients (P=0.02). There were larger and statistically
significant diCerences for time to death from any cause 65 years old and has a life expectancy without prostate
cancer of #15 years. He has a rising PSA level afterin M0 patients, as well as time to death from prostate
cancer in M0 and M1 patients; 203 patients died from radical prostatectomy or radiotherapy. What does early
treatment oCer? As detailed above, the median time toprostate cancer in the immediate and 257 in the delayed
treatment arm, a diCerence of 54 cancer deaths, which metastatic progression in this case is 6–8 years and
depends on the original tumour characteristics. It is wellexplains all significant diCerences encountered, as time
to death from causes other than prostate cancer did not known and understood that endocrine treatment pro-
longs time to progression. Treatment with a 5a-reductasediCer between the treatment groups. The authors report
that of the 54 cases who died in the delayed treatment inhibitor in this situation will delay the rise of PSA and
of progression by 9 months [27]. It has been shown thatarm, 29 (54%) never received endocrine treatment. The
participants in this protocol were encouraged to manage more aggressive endocrine treatment will then decrease
the PSA level and will again produce a period of PSA-their patients ‘according to their clinical practice’; a
follow-up form was requested once a year. Bone scans based remission of probably several years, say three.
This means that a patient who chooses early endocrinewere not available for many of the participants. If
progressive disease had been diagnosed with a 3-monthly treatment in this situation is likely to be treated for
9–12 years until he experiences metastatic progression.follow-up and treated appropriately, how would that
have changed the final outcome? Is it inevitable to miss If that occurs, there will be no eCective treatment in
reserve. In the meantime, he has lost libido and potency,progression in some patients? Ongoing EORTC studies
on the same issue do not confirm this possibility. and has encountered several side-eCects, elaborated
below. In the worst case, he has suCered a hip fracture
or other spontaneous fracture due to osteoporosis, which
What to do?
could have been avoided otherwise. At the time of
metastatic progression, unfortunately no eCective thera-Other studies, mainly at the level of the EORTC GU
Group, are currently underway. Results based on at least peutic options are available and the patient will then
probably succumb within a year.1500 patients in two protocols comparing early vs
delayed treatment in lymph node-positive disease (EORTC What does delayed treatment oCer? The patient will
have to live with the knowledge of a rising PSA level. If30846), and in M0 cases with all local stages (EORTC
protocol 30891) will be ready for final evaluation in the this keeps him awake at night, he is symptomatic and
must be treated. In my experience of this situation,near future. Preliminary evaluation of these protocols
has shown that only very few patients will ever progress explanations such as mentioning the well-known median
times until metastatic disease occurs help the patients toand die from prostate cancer without receiving endocrine
treatment. Also, the serious complications (spontaneous understand better what they may and may not expect.
Also, to indicate that metastatic disease is rarely seenfractures, paraplegia, etc.) described in the MRC study
are rare in these studies. Clearly, a patient with locally with PSA values of <100–200 ng/mL gives them an
idea of how relative a PSA increase from, e.g. 2 toadvanced or metastatic prostate cancer, in whom endo-
crine treatment is delayed, has to have the opportunity 4 ng/mL, may be. Meanwhile, during watchful waiting
the patient can enjoy a normal libido and sexual life. Heand must be ready to undergo regular follow-up examin-
ations, probably at 3-monthly intervals. is not at risk from the side-eCects of endocrine treatment
and, if progression finally occurs, an eCective treatmentIn the author’s view, conclusive data which dictate
either the use of early or delayed treatment are currently will be in reserve.
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In the author’s view, both options should be explained
to patients and they should be given a choice, as long
as clear advantages for disease-specific and overall sur-
vival have not been shown. The EORTC GU Group
protocol 30846, of which the randomization scheme is
shown in Fig. 3, has been in progress since 1984. About
290 patients have been included. Despite very large
diCerences in time to progression in the two arms, and
despite two reviews by the Data Monitoring Committee
that functions as an ethical supervisory body of this
study, the protocol has not been discontinued because
apparently there have been no diCerences in survival;
the situation around protocol 30891 is similar.
Side-eVects of endocrine treatment
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Fig. 4. The time to loss of ejaculation in 75 previously potentEndocrine treatment leads to loss of libido and potency;
patients with metastatic prostate cancer treated by either flutamideit is thought that after castration this eCect is immediate
(green) or cyproterone acetate (red) in a randomized study (EORTCand it seems to be related to the elimination of testicular
protocol 30892).
androgens. However, in a classic paper, Ellis et al. [28]
found that after castration, treatment with oestrogens
as described above. Daniell [30] described an importantor the combination of both regimens, 16 of 38 previously
increase in osteoporosis and osteoporotic fractures afterpotent patients remained potent for prolonged periods.
orchidectomy in comparison with an age-matched popu-This finding is confirmed by recent data relating to the
lation of men with intact testicular function, over ause of antiandrogen monotherapy [29]. These data are
period of 9 years; the results are depicted in Fig. 5. Thederived from EORTC GU Group protocol 30892, a ran-
occurrence of a decrease in bone mineral density, whichdomized study of patients with metastatic prostate cancer
leads to osteoporotic fractures if critical limits are passed,treated by either flutamide or CPA monotherapy.
is clearly related to the decrease of circulating androgens.Figure 4 shows the time to loss of ejaculation in 75
This is also confirmed by Eriksson et al. [31], andpreviously potent patients. The Kaplan-Meier projections
McGrath and Diamond [32].of loss of other sexual functions are reported elsewhere
The pale appearance of many patients under endocrine[29]. The important message is that the loss of sexual
treatment is caused by significant anaemia that resultsfunction under monotherapy with either a pure or a
from low androgen levels. This has been quantifiedsteroidal antiandrogen is a slow process. It does not
recently by Strum et al. [33]. A probable mechanismseem to be true that sexual function is preserved with
and the immediate recovery of red blood cell counts withflutamide monotherapy, as has been claimed previously.
androgen substitution have been described by WeberHowever, 10–20% of patients remain potent over obser-
et al. [34].vation times of 2–6 years with both antiandrogens; the
mechanism is unexplained. These observations open
possibilities for new strategies in the use of
antiandrogens.
Other side-eCects of endocrine treatment are also time-
dependent and may not become relevant with the short
treatment periods usually necessary for the management
of metastatic disease. However, they may be very rel-
evant for prolonged periods of endocrine treatment, such
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Fig. 5. The cumulative incidence of first osteoporosis fractures inFig. 3. The randomization scheme of the EORTC protocol 30846,
early vs delayed endocrine treatment in patients with pN1–3 men with prostate cancer with (green) and without (red)
orchidectomy. (From Daniell [30] with permission).prostate cancer.
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(b) was shown beyond doubt to be more eCective if (a) are not very relevant considering the seriousness
of the diseaseapplied early
(c) was shown beyond doubt to be equally eCective (b) depend strongly on the duration of treatment
(c) usually occur only after prolonged treatmentwith delayed application (VACURG studies)
(d) the timing is subject to patient choice and (d) are identical to symptoms of the male
climacteriumpreference
9 Intermittent endocrine treatment
6 Quality of life:
(a) is the treatment of choice in all men who wish
(a) is better with early endocrine treatment
to remain potent
(b) was shown to be improved with delayed treat-
(b) has been shown to be comparable to standard
ment because patients remain potent
treatment for survival
(c) is likely to depend on the duration of treatment
(c) is currently the subject of phase III studies
(d) has never been studied in patients with pros-
(d) may be an option for men who do not show a
tate cancer
favourable initial PSA response
10 Neo-adjuvant endocrine treatment:7 Libido and potency:
(a) are lost very slowly with antiandrogen treatment (a) is probably eCective before radiotherapy in T3
disease(b) sexual function is generally preserved under
treatment with flutamide (b) leads to a decrease of positive margins in T3
cases undergoing radiotherapy(c) are always lost after castration
(d) are important elements of quality of life for all (c) is usually given for 6 months
(d) leads to a significant advantage in time tomen with prostate cancer
progression if given for 6 months before radical
prostatectomy8 Side-eCects of endocrine treatment:
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